AOA Dx Inc announced today that they have closed a $7 million funding round led by Avestria Ventures, AlleyCorp, The Helm, RH Capital, Olive Tree Capital, Tencent, and other notable investors.
The funding will be used to further develop the next generation of AOA’s ovarian cancer detection technology, AKRIVIS GD, and expand their growing team. Currently, there are no reliable ovarian cancer biomarkers that detect early-stage disease.
AOA Dx Inc was a 2021 MassNextGen awardee, a program that helps fortify the ability of women-led companies to leverage additional sources of capital and support to bring cutting edge innovation to the marketplace.